Application value of serum Syndecan-1, endocan-1 and qSOFA scores in diagnosis and prognosis of sepsis

doi:10.11958/20241664

Abstract

Abstract:

Objective To explore the application value of serum Syndecan-1 and endocan-1 combined with rapid sequential organ failure (qSOFA) score in the diagnosis and prognosis of sepsis. Methods The severity of 118 patients with sepsis was divided into the general sepsis group (48 cases), the severe sepsis group (42 cases) and the septic shock group (28 cases). According to the prognosis, patients were divided into the death group (n=32) and the survival group (n=86). A total of 118 healthy volunteers were selected as the control group. Serum Syndecan-1 and endocan-1 levels were detected by enzyme-linked immunosorbent assay (ELISA). The value of serum Syndecan-1, endocan-1 and qSOFA scores in the early diagnosis and prognosis of sepsis was analyzed by receiver operating characteristic (ROC) curve, and the area under the curve (AUC) was compared. Results Compared with the control group, levels of Syndecan-1, endocan-1 and qSOFA scores were increased in the study group (P<0.05). The serum Syndecan-1, endocan-1 and qSOFA score in the general sepsis group, the severe sepsis group and the septic shock group were significantly increased in sequence (P<0.05). ROC curve analysis showed that the AUC of serum Syndecan-1, endocan-1 and qSOFA score in the diagnosis of sepsis (0.967) were higher than that of Syndecan-1 (AUC=0.868), endocan-1 (AUC=0.798) and qSOFA score (AUC=0.873) alone (Z=6.541, 5.495 and 6.395, P<0.001). Compared with the survival group, the levels of Syndecan-1, endocan-1 and qSOFA scores were significantly increased in the death group (P<0.05). The combined prediction of AUC (0.983) was higher than that of Syndecan-1 (AUC=0.814), endocan-1 (AUC=0.834) and qSOFA score (AUC=0.924) alone (Z=6.596, 9.268 and 6.904, P<0.001). Conclusion Serum levels of Syndecan-1, endocan-1 and qSOFA are increased in patients with sepsis, and the combination of the three has higher clinical value in the diagnosis and prognosis evaluation of sepsis.

Key words: sepsis, ROC curve, Syndecan-1, endocan-1, qSOFA

CLC Number:

R631.2，R446.1

Figures/Tables 8

References 17

[1]	GUO Q, LIAO H, HAO S, et al. TSPO exacerbates sepsis-induced cardiac dysfunction by inhibiting p62-mediated autophagic flux via the ROS-RIP1/RIP3-exosome axis[J]. Free Radic Biol Med, 2024, 12(2):891-899. doi:10.1093/hmg/ddn423.
[2]	IWASHYNA T J, ELY E W, SMITH D M, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis[J]. JAMA, 2010, 304(16):1787-1794. doi:10.1001/jama.2010.1553.
[3]	PAN S, LV Z, WANG R, et al. Sepsis-induced brain dysfunction: pathogenesis, diagnosis, and treatment[J]. Oxid Med Cell Longev, 2022, 2022:1328729. doi:10.1155/2022/1328729.
[4]	ZHANG X, ZHAO Y, LIU L, et al. Syndecan-1:a novel diagnostic and therapeutic target in liver diseases[J]. Curr Drug Targets, 2023, 24(15):1155-1165. doi:10.2174/0113894501250057231102061624.
[5]	GAUDET A, PORTIER L, PRIN M, et al. Endocan regulates acute lung inflammation through control of leukocyte diapedesis[J]. J Appl Physiol(1985),2019, 127(3):668-678. doi:10.1152/japplphysiol.00337.2019.
[6]	CHRISTENSEN E E, PREBENSEN C H, MARTINSEN A B, et al. Mortality and sequential organ failure assessment score in patients with suspected sepsis:the impact of acute and preexisting organ failures and infection likelihood[J]. Crit Care Explor, 2023, 5(2):865-876. doi:10.1097/CCM.0b013e31819def97.
[7]	中国医师协会急诊医师分会, 中国研究型医院学会休克与脓毒症专业委员会. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 中国急救医学, 2018, 38(9):741-756.
	Chinese Medical Doctor Association Emergency Physicians Branch, Shock and Sepsis Committee of Chinese Society of Research Hospitals. Guidelines for emergency treatment of sepsis/septic shock in China(2018)[J]. Chinese Emergency Medicine, 2018, 38(9):741-756.
[8]	SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock(sepsis-3)[J]. JAMA, 2016, 315(8):801-810. doi:10.1001/jama.2016.0287.
[9]	NAGAOKA I, TAMURA H, REICH J. Therapeutic potential of cathelicidin peptide LL-37,an antimicrobial agent,in a murine sepsis model[J]. Int J Mol Sci, 2020, 21(17):5973-5982. doi:10.3390/ijms21175973.
[10]	罗许, 刘善收, 王欢, 等. 灌注边界区域联合快速序贯器官衰竭评分对脓毒症的早期诊断价值[J]. 中国急救医学, 2023, 43(11):880-886.
	LUO X, LIU S S, WANG H, et al. Early diagnostic value of PBR combined with qSOFA in sepsis[J]. Chinese Journal of Critical Care Medicine, 2023, 43(11):880-886. doi:10.3969/j.issn.1002-1949.2023.11.006.
[11]	ZHANG D, LI L, CHEN Y, et al. Syndecan-1,an indicator of endothelial glycocalyx degradation,predicts outcome of patients admitted to an ICU with COVID-19[J]. Mol Med, 2021, 27(1):151. doi:10.1186/s10020-021-00412-1.
[12]	HADIGAL S, KOGANTI R, YADAVALLI T, et al. Heparanase-regulated syndecan-1 shedding facilitates herpes simplex virus 1 egress[J]. J Virol, 2020, 94(6):5-10. doi:10.1128/jvi.01672-19.
[13]	SUN T, WANG Y, WU X, et al. Prognostic value of syndecan-1 in the prediction of sepsis-related complications and mortality:a Meta-analysis[J]. Front Public Health, 2022, 10:870065. doi:10.3389/fpubh.2022.870065.
[14]	PUDJIADI A H, SAIDAH F, ALATAS F S. Correlation between syndecan-1 level and PELOD-2 score and mortality in pediatric sepsis[J]. Rev Bras Ter Intensiva, 2021, 33(4):549-556. doi:10.5935/0103-507X.20210083.
[15]	杨登元, 朱宝华, 张凯, 等. 内皮细胞特异性分子1在早期预测肠源性脓毒症急性呼吸窘迫综合征的价值[J]. 成都医学院学报, 2020, 15(5):611-614.
	YANG D Y, ZHU B H, ZHANG K, et al. Value of endothelial cell-specific molecule-1 in early prediction of gut-origin sepsis with acute respiratory distress syndrome[J]. Journal of Chengdu Medical College, 2020, 15(5):611-614. doi:10.3969/j.issn.1674-2257.2020.05.016.
[16]	裴戌锋, 严友纪, 黄芳, 等. 血清ESM-1、VE-Cad、CC16水平与脓毒症并发急性呼吸窘迫综合征患者炎性因子及预后的关系研究[J]. 现代生物医学进展, 2022, 22(13):2570-2574.
	PEI X F, YAN Y J, HUANG F, et al. Relationship study between serum ESM-1,VE-Cad,CC16 levels and inflammatory factors and prognosis in patients with sepsis complicated with acute respiratory distress syndrome[J]. Progress in Modern Biomedicine, 2022, 22(13):2570-2574. doi:10.13241/j.cnki.pmb.2022.13.033.
[17]	周莹, 王雅宁, 吴爽, 等. 灯盏花素对脓毒症急性肺损伤患者炎性因子、凝血功能的影响及疗效研究[J]. 天津医药, 2023, 51(4):409-413.
	ZHOU Y, WANG Y N, WU S, et al. Effects and clinical efficacy of breviscapine on inflammatory factors and coagulation function in patients with septic acute lung injury[J]. Tianjin Med J, 2023, 51(4):409-413. doi:10.11958/20221250.

组别	hs-CRP/（mg/L）	PCT/（μg/L）	IL-6/（μg/L）	LDL-C/（mmol/L）
对照组	13.40±2.10	0.70±0.12	15.08±1.65	3.21±0.39
研究组	20.03±2.55	0.98±0.15	21.18±2.35	3.75±0.40
t	21.802^＊＊	15.834^＊＊	23.077^＊＊	10.500^＊＊
组别		TC/（mmol/L）	TG/（mmol/L）	HDL-C/（mmol/L）
对照组		2.15±0.29	2.12±0.28	1.32±0.15
研究组		3.91±0.44	2.51±0.26	1.11±0.13
t		36.280^＊＊	11.087^＊＊	11.492^＊＊

组别	hs-CRP/（mg/L）	PCT/（μg/L）	IL-6/（μg/L）	LDL-C/（mmol/L）
对照组	13.40±2.10	0.70±0.12	15.08±1.65	3.21±0.39
研究组	20.03±2.55	0.98±0.15	21.18±2.35	3.75±0.40
t	21.802^＊＊	15.834^＊＊	23.077^＊＊	10.500^＊＊
组别		TC/（mmol/L）	TG/（mmol/L）	HDL-C/（mmol/L）
对照组		2.15±0.29	2.12±0.28	1.32±0.15
研究组		3.91±0.44	2.51±0.26	1.11±0.13
t		36.280^＊＊	11.087^＊＊	11.492^＊＊

组别	Syndecan-1/（μg/L）	endocan-1/（μg/L）	qSOFA评分/分
对照组	3.95±0.58	6.85±0.70	0.12±0.01
研究组	4.95±0.59	7.74±0.79	1.45±0.21
t	13.130^＊＊	9.159^＊＊	68.720^＊＊

组别	Syndecan-1/（μg/L）	endocan-1/（μg/L）	qSOFA评分/分
对照组	3.95±0.58	6.85±0.70	0.12±0.01
研究组	4.95±0.59	7.74±0.79	1.45±0.21
t	13.130^＊＊	9.159^＊＊	68.720^＊＊

组别	n	Syndecan-1/ （μg/L）	endocan-1/ （μg/L）	qSOFA评分/分
一般脓毒症组	48	4.32±0.60	7.10±0.80	1.25±0.20
严重脓毒症组	42	5.05±0.59^a	7.95±0.79^a	1.46±0.22^a
脓毒症休克组	28	5.86±0.58^ab	8.52±0.78^ab	1.76±0.23^ab
F		60.899^＊＊	30.744^＊＊	50.114^＊＊